Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease

Language
en
Document Type
Article
Issue Date
2016-08-04
Issue Year
2015
Authors
Hellwig, Konstantin
Kvartsberg, Hlin
Portelius, Erik
Andreasson, Ulf
Oberstein, Timo Jan
Lewczuk, Piotr
Blennow, Kai
Kornhuber, Johannes
Maler, Juan Manuel
Zetterberg, Henrik
Editor
Abstract

Introduction Neuroinflammation and synaptic degeneration are major neuropathological hallmarks in Alzheimer’s disease (AD). Neurogranin and YKL-40 in cerebrospinal fluid (CSF) are newly discovered markers indicating synaptic damage and microglial activation, respectively. Methods CSF samples from 95 individuals including 39 patients with AD dementia (AD-D), 13 with mild cognitive impairment (MCI) due to AD (MCI-AD), 29 with MCI not due to AD (MCI-o) and 14 patients with non-AD dementias (non-AD-D) were analyzed for neurogranin and YKL-40. Results Patients with dementia or MCI due to AD showed elevated levels of CSF neurogranin (p < 0.001 for AD-D and p < 0.05 for MCI-AD) and YKL-40 (p < 0.05 for AD-D and p = 0.15 for MCI-AD) compared to mildly cognitively impaired subjects not diagnosed with AD. CSF levels of neurogranin and YKL-40 did not differ between MCI not due to AD and non-AD dementias. In AD subjects no correlation between YKL-40 and neurogranin was found. The CSF neurogranin levels correlated moderately with tau and p-tau but not with Aβ42 or the MMSE in AD samples. No relevant associations between YKL-40 and MMSE or the core AD biomarkers, Aβ42, t-tau and p-tau were found in AD subjects. Conclusions Neurogranin and YKL-40 are promising AD biomarkers, independent of and complementary to the established core AD biomarkers, reflecting additional pathological changes in the course of AD.

Journal Title
Alzheimer's Research & Therapy
Volume
7
Citation
Alzheimer's Research & Therapy 7 (2015):S.74-81. <https://alzres.biomedcentral.com/articles/10.1186/s13195-015-0161-y>
DOI
Zugehörige ORCIDs